What's breaking now, across thousands of outlets.
(RTTNews) - Tuesday, uniQure (QURE) reported new data showing its investigational gene therapy AMT-130 continued to slow measures of Huntington's disease progression in patients followed for up to 48 months.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
TORONTO — Choice Properties Real Estate Investment Trust (“Choice Properties” or the “Trust”) (TSX: CHP.UN) announced today that it will be reporting third quarter 2026 results on Thursday, November…
Smart ring maker Oura has paused plans to go public, citing uncertain market conditions. The company’s initial public offering (IPO) had been slated for this week but has now been postponed “despite…
Reuters got a look at Anthropic's IPO filing, and OpenAI scrapped a model release over safety concerns.
OAKVILLE, Ontario — GL Chemtec International Limited (“GL Chemtec” or “the Company”), a leader in the research, development, and GMP production of complex active pharmaceutical ingredients (API’s) and…
Raven is an institutional market-maker for prediction markets, generating constant buy and sell orders on contracts.
Strategic Advisor to Support Commercial Partnerships, Economic Development and Growth Initiatives Across Texas and the Southern United States DALLAS — Tactical Resources Corp.
